% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • larshansson18 larshansson18 Jun 27, 2011 11:21 AM Flag

    Excellent news on the annual meeting

    1. Amiket is a potential billion market opportunity fro the cancer pain path and even more fore the broader path neuropathic pain. "Make No mistake about it!", Talley stressed.

    2. Epicept have taken a more precise step for the FDA-meeting: SPA-protocol and fast track application for - Amiket aswell! Very good news, probably after communicating with interested parties at the negotiation table. After a deal, Big Pharma takes the leading role here, concerning that application.

    3. Still - Ceplene phase III to start before year end.

    4. Above the credit and new expenditures, Epicept is financed for at least one year.

    5. News today that Denmark also have been given Ceplene a price, USD 68 824 for one whole treatment! (Remember Talley hoped for 40 000+ two years ago.)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.3789-0.0011(-0.29%)Aug 24 3:59 PMEDT